cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Akero Therapeutics Inc
9 own
6 watching
Current Price
$47.96
$0.25
(0.52%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,237.69M
52-Week High
52-Week High
54.88
52-Week Low
52-Week Low
7.52
Average Volume
Average Volume
0.34M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,237.69M
icon52-Week High54.88
icon52-Week Low7.52
iconAverage Volume0.34M
iconDividend Yield--
iconP/E Ratio--
What does the Akero Therapeutics Inc do?
Akero Therapeutics, Inc. are a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Their initial focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. Their lead product candidate, AKR-001, which they are developing as a potential treatment for patients with NASH, is an analog of fibroblast growth factor 21, or FGF21. FGF21 is an endogenously-expressed hormone that regulates metabolism of lipids, carbohydrates and proteins throughout the body. FGF21 also plays a critical role in protecting many types of cells from various forms of stress. FGF21 agonists have shown evidence of therapeutic benefit in clinical trials of patients with NASH, many of whom are dyslipidemic and insulin resistant. In previous clinical trials in patients with type 2 diabetes, or T2D, administration of AKR-001 was associated with a substantial improvement in lipid metabolism and insulin sensitivity. They believe these data demonstrate AKR-001's potential to serve as a cornerstone for the treatment of NASH. They plan to initiate a Phase 2a clinical trial for AKR-001 in NASH patients with fibrosis in the middle of 2019. Akero Therapeutics, Inc. were incorporated in January 2017 under the laws of the State of Delaware under the name Pippin Pharmaceuticals, Inc. On May 16, 2018, they changed their name to Akero Therapeutics, Inc. Their principal executive offices are located at 170Harbor Way, 3rd Floor, South San Francisco, CA 94080.
Read More
How much money does Akero Therapeutics Inc make?
News & Events about Akero Therapeutics Inc.
Globe Newswire
25days ago
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as ...
Globe Newswire
1month ago
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the ...
Globe Newswire
3 months ago
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the...
Ticker Report
3 months ago
Akero Therapeutics, Inc. (NASDAQ:AKRO Get Rating) Director Seth Loring Harrison sold 4,515 shares of the businesss stock in a transaction dated Tuesday, October 25th. The shares were sold at an average price of $44.92, for a total value of $202,813.80. Following the completion of the ...
Ticker Report
4 months ago
Akero Therapeutics, Inc. (NASDAQ:AKRO Get Rating) insider Timothy Rolph sold 45,000 shares of the companys stock in a transaction on Friday, September 30th. The stock was sold at an average price of $32.72, for a total value of $1,472,400.00. Following the transaction, the insider now...
Frequently Asked Questions
Frequently Asked Questions
What is Akero Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Akero Therapeutics Inc shares?
plus_minus_icon
How can I buy Akero Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Akero Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Akero Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Akero Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Akero Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Akero Therapeutics Inc?
plus_minus_icon
What percentage is Akero Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Akero Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$47.96
$0.25
(0.52%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00